Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: Rocket Red who wrote (4300)	8/9/2009 5:58:39 PM
From: T.F.	Read Replies (1) \| Respond to of 233904

GAP drug could easily be fast tracked to human tests as it is effective against chemo resistant cancers as per OHRI results. The FDA could easily fast track their drug after NCI results come in as was done for GLEEVAC in 2001 stockhouse.com If that happens we're looking at $2.00 a share for GAP. I suggest you hold your freebies for a while. If GAP shows efficacy in human trials as it has done in all other tests so far then look out. Their drug will be a replacement or companion agent for chemotherapy and GAP will be $10.00 a share or taken out before they get that far by big Pharma.